TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33629506

Group type: EXPERIMENTAL
Intervention: Caloric restriction diet with fiber supplementation (10 g day-1 inulin + 10 g day-1 resistant maltodextrin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 80
Study: 33072209

Group type: EXPERIMENTAL
Intervention: Transformational management properties of hospital managers
Number of subjects: 346
Study: 33185050

Group type: EXPERIMENTAL
Intervention: 40 mg/m² PLD (experimental arm)
Number of subjects: 470

Group type: COMPARATOR
Intervention: 50 mg/m² PLD (standard arm)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Standard arm (50 mg/m² PLD)
Number of subjects: 470
Study: 32972635

Group type: EXPERIMENTAL
Intervention: 5% Pueraria mirifica gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 34080764

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Kinesiotaping (sham KT)
Number of subjects: 50
Study: 33213506

Group type: EXPERIMENTAL
Intervention: 8-week integrated treatment
Number of subjects: 214

Group type: COMPARATOR
Intervention: Gambling only control condition
Number of subjects: 214
Study: 34153946

Group type: EXPERIMENTAL
Intervention: Coherent transport regime for a clean wire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non‐coherent transport regime with dephasing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of dephasing
Number of subjects: 0
Study: 32453183

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Baseline QTc length
Number of subjects: 19
Study: 34811971

Group type: EXPERIMENTAL
Intervention: Nocturnal recorded home oximetry (RHO)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 53
Study: 32776286

Group type: EXPERIMENTAL
Intervention: SOTOS (silent operation theatre optimisation system)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no SOTOS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SOTOS
Number of subjects: 32
Study: 36417447

Group type: EXPERIMENTAL
Intervention: Case-based e-flipped workshop
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Case-based online workshop
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 33161779

Group type: EXPERIMENTAL
Intervention: Transverse DMO
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chevron DMO
Number of subjects: 18
Study: 35710599

Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (LIRA 3 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 82
Study: 33470751

Group type: EXPERIMENTAL
Intervention: I-eHealth
Number of subjects: 36

Group type: COMPARATOR
Intervention: RCT-eHealth
Number of subjects: 36

Group type: COMPARATOR
Intervention: RCT-control
Number of subjects: 36
Study: 35751710

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping in diabetic pregnancies
Number of subjects: 261

Group type: COMPARATOR
Intervention: Immediate cord clamping in diabetic pregnancies
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping in normal pregnancies
Number of subjects: 261

Group type: COMPARATOR
Intervention: Immediate cord clamping in normal pregnancies
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping in diabetic pregnancies vs normal pregnancies
Number of subjects: 261
Study: 32925256

Group type: EXPERIMENTAL
Intervention: Supraclavicular block (SCB) with ropivacaine 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retroclavicular block (RCB) with ropivacaine 0.5%
Number of subjects: 40
Study: 34347626

Group type: EXPERIMENTAL
Intervention: Fatigue self-management program (fatigue: take control)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Multiple sclerosis education program (multiple sclerosis: take control)
Number of subjects: 218
Study: 33349200

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EC)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 585
Study: 33260697

Group type: EXPERIMENTAL
Intervention: W@W-App (intervention group; n = 90)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Active comparison group (A-CG; n = 51)
Number of subjects: 141
Study: 34553652

Group type: EXPERIMENTAL
Intervention: GDM with insulin therapy (Group 1)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: GDM with diet (Group 2)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Healthy controls (Group 3)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: GDM groups (Group 1 and Group 2)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Maternal side SWE velocities
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Foetal side SWE velocities in GDM groups
Number of subjects: 319
Study: 33849093

Group type: EXPERIMENTAL
Intervention: Peer support (WeChat group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Peer support (face-to-face group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: WeChat group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intervention group (WeChat and face-to-face)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 36164033

Group type: EXPERIMENTAL
Intervention: A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: A+AVD
Number of subjects: 1334

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1334
Study: 33625251

Group type: EXPERIMENTAL
Intervention: Causal association with CAD
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Impact on lifespan potential
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Drug targets identified
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Single-cell expression analysis
Number of subjects: 840
Study: 35804991

Group type: EXPERIMENTAL
Intervention: Epirubicin and Cyclophosphamide (EC)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Docetaxel and Cyclophosphamide (TC)
Number of subjects: 275
Study: 35637615

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Education/support (attention control)
Number of subjects: 40
Study: 34842130

Group type: EXPERIMENTAL
Intervention: Multi-level, multi-component obesity intervention
Number of subjects: 422

Group type: COMPARATOR
Intervention: Comparison (Control)
Number of subjects: 422
Study: 32863126

Group type: EXPERIMENTAL
Intervention: Subciliary approach
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Subtarsal approach
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transconjunctival approach
Number of subjects: 45
Study: 36113495

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 34077482

Group type: EXPERIMENTAL
Intervention: Open-label placebos remotely
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34694880

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (80/480 mg)
Number of subjects: 8
Study: 33538777

Group type: EXPERIMENTAL
Intervention: Initial reports of phase 3 RCTs
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Updated reports of phase 3 RCTs
Number of subjects: 207
Study: 32412683

Group type: EXPERIMENTAL
Intervention: Community-based paediatrician (IC)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Tertiary-hospital specialist allergy clinic (CC)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Community-based model of care (IC)
Number of subjects: 296
Study: 36073634

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (6 mg bolus followed by 6 mg/h infusion)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 35297106

Group type: EXPERIMENTAL
Intervention: Tamsulosin with Ryutanshakanto
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin and Hachimijiogan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin with Hachimijiogan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 0
Study: 32555148

Group type: EXPERIMENTAL
Intervention: Mixed Meal (MM) - 120 mL, 523 kJ (125 kcal) four times/day for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Electrolyte Solution (ES) - 50 kJ (12 kcal) four times/day for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of weight change between MM and ES
Number of subjects: 16
Study: 35841104

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural therapy (12-week intervention consisting of five patient-therapist sessions and five to eight individualized web-based therapy modules with email support)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list condition (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural therapy
Number of subjects: 100
Study: 34051178

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1010
Study: 32365097

Group type: EXPERIMENTAL
Intervention: Astodrimer 0.5% Gel
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Astodrimer 1% Gel
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Astodrimer 3% Gel
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 132
Study: 36147650

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (2 sessions of 90 min per week for 12 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting-list control group (maintained usual daily routines for 12 weeks)
Number of subjects: 39
Study: 33258213

Group type: EXPERIMENTAL
Intervention: Nasal High-flow Oxygen (NHF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COT)
Number of subjects: 37
Study: 33483868

Group type: EXPERIMENTAL
Intervention: 0.1% octenidine mouthwash
Number of subjects: 201
Study: 32032809

Group type: EXPERIMENTAL
Intervention: Parryscope technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flow technique
Number of subjects: 60
Study: 32038465

Group type: EXPERIMENTAL
Intervention: Active tDCS before exercise on the treadmill
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS before exercise on the treadmill
Number of subjects: 12
Study: 35786002

Group type: EXPERIMENTAL
Intervention: Tenecteplase (exact dosage not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33835016

Group type: EXPERIMENTAL
Intervention: Test product (4 mg pridinol mesylate)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Reference product (4 mg pridinol mesylate)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 34
Study: 35098980

Group type: EXPERIMENTAL
Intervention: MTCC intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tai-Chi Chuan intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 33285763

Group type: EXPERIMENTAL
Intervention: Home-based reablement group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 36076009

Group type: EXPERIMENTAL
Intervention: Atez/Bev (atezolizumab and bevacizumab)
Number of subjects: 426
Study: 34479219

Group type: EXPERIMENTAL
Intervention: Supplemental sensory feedback through vibrotactile stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback policy (slow)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedforward policy (fast)
Number of subjects: 0
Study: 36476534

Group type: EXPERIMENTAL
Intervention: Hex‐V
Number of subjects: 194

Group type: COMPARATOR
Intervention: Hex‐IH
Number of subjects: 194
Study: 33855195

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 72
Study: 32936713

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Trastuzumab + chemotherapy
Number of subjects: 275
Study: 36482326

Group type: EXPERIMENTAL
Intervention: Ivermectin plus acetaminophen
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo plus acetaminophen
Number of subjects: 66
Study: 33796986

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS stimulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 52
Study: 35242882

Group type: EXPERIMENTAL
Intervention: C. lacerata (500 mg/capsule) for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 90
Study: 34063306

Group type: EXPERIMENTAL
Intervention: HEAL program (healthy empowered active lifestyles) intervention for 12 weeks
Number of subjects: 20
Study: 33047653

Group type: EXPERIMENTAL
Intervention: Classroom intervention to promote glasses wearing (including classroom tracker, verbal reminders, and incentives)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Classroom intervention to promote glasses wearing
Number of subjects: 44
Study: 34111978

Group type: EXPERIMENTAL
Intervention: Machine learning-based CT radiomics features using Random Forest algorithm
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Machine learning-based CT radiomics features
Number of subjects: 81
Study: 32666831

Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 0
Study: 35896302

Group type: EXPERIMENTAL
Intervention: Family customised online FOCUS programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Attention control group (no elements of the FOCUS programme)
Number of subjects: 142
Study: 34619441

Group type: EXPERIMENTAL
Intervention: One-day Acceptance and Commitment Therapy (ACT) workshop
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 33202928

Group type: EXPERIMENTAL
Intervention: Equine Riding Simulator (ERS) program, 12 weeks, 3 times per week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 80
Study: 35473594

Group type: EXPERIMENTAL
Intervention: Exercise targeting balance and lower limb strength (intervention group)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Exercise targeting upper limb strength (control group)
Number of subjects: 617
Study: 33806051

Group type: EXPERIMENTAL
Intervention: Self-help app for Syrian refugees with PTSS
Number of subjects: 133
Study: 35760595

Group type: EXPERIMENTAL
Intervention: Single thoracic SMT with a total peak force of 800N
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single thoracic SMT with a total peak force of 400N
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (preload only)
Number of subjects: 19
Study: 33462716

Group type: EXPERIMENTAL
Intervention: DCIS score low-risk patients
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: DCIS score intermediate-risk patients
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: DCIS score high-risk patients
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: ER + disease with high-risk score
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: ER + disease with intermediate-risk score
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: ER - disease with low-risk score
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: ER - disease with intermediate-risk score
Number of subjects: 4255

Group type: EXPERIMENTAL
Intervention: ER - disease with high-risk score
Number of subjects: 4255
Study: 36394148

Group type: EXPERIMENTAL
Intervention: Anamorelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33556391

Group type: EXPERIMENTAL
Intervention: Large portion (200 g) consumed at home
Number of subjects: 119

Group type: COMPARATOR
Intervention: Small portion (100 g) consumed at home
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Large portion (200 g) consumed in laboratory
Number of subjects: 119

Group type: COMPARATOR
Intervention: Small portion (100 g) consumed in laboratory
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Standard laboratory setting
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Semi-naturalistic laboratory setting
Number of subjects: 119
Study: 35283003

Group type: EXPERIMENTAL
Intervention: Hybrid repair (HR)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Open reconstruction (OR)
Number of subjects: 202
Study: 32031879

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (goal to reduce fat intake to 20% of energy and increase vegetable, fruit, and grain intake)
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 48835
Study: 33482315

Group type: EXPERIMENTAL
Intervention: Ammoxetine 2.5, 7.5, 15, 30, 45, 65, 100 mg (single-dose)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ammoxetine 15, 30, 45 mg (multiple-dose for 8 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (single-dose and multiple-dose)
Number of subjects: 94
Study: 34221032

Group type: EXPERIMENTAL
Intervention: Oral hygiene regimen (OHR) including bioavailable stannous fluoride dentifrice, oscillating‐rotating electric toothbrush, cetylpyridinium chloride rinse, and floss
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care products (sodium fluoride dentifrice and manual toothbrush)
Number of subjects: 107
Study: 32919092

Group type: EXPERIMENTAL
Intervention: Nexxo-training (experimental group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Active-control group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Passive-control group
Number of subjects: 108
Study: 36817344

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 43
Study: 32172314

Group type: EXPERIMENTAL
Intervention: Drainage (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drainage (group B)
Number of subjects: 80
Study: 34391247

Group type: EXPERIMENTAL
Intervention: Yoga module (5 days per week for 6 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study: 32819949

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) with stretching protocol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Percutaneous Needle Electrolysis (PNE) with stretching protocol
Number of subjects: 102
Study: 34990712

Group type: EXPERIMENTAL
Intervention: ABCC1 inhibitor probenecid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 35870435

Group type: EXPERIMENTAL
Intervention: Teach‐to‐Goal (TTG) education
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Virtual Teach‐to‐Goal (V‐TTG) education
Number of subjects: 394

Group type: COMPARATOR
Intervention: Brief Intervention (BI) education
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: High health literacy
Number of subjects: 394

Group type: COMPARATOR
Intervention: Low health literacy
Number of subjects: 394
Study: 33244045

Group type: EXPERIMENTAL
Intervention: Comprehensive corrective exercise program (CCEP) for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CCEP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 24
Study: 35555662

Group type: EXPERIMENTAL
Intervention: Creatine Nitrate (CN: 5 g/day + 0.675 g/day of maltodextrin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF: 400 mg/day + 5 g/day of maltodextrin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Creatine Nitrate + Caffeine (CN+CAF: 5 g/day of creatine nitrate + 400 mg/day of caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL: 5.4 g/day of maltodextrin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All conditions (CN, CAF, CN+CAF, PL)
Number of subjects: 12
Study: 36252718

Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg IV (perioperatively)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 36654288

Group type: EXPERIMENTAL
Intervention: Bumetanide 0.5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34375695

Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioabsorbable scaffolds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 0
Study: 33840486

Group type: EXPERIMENTAL
Intervention: Haylage (grass-alfalfa mix)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Hay (alfalfa)
Number of subjects: 7
Study: 33175600

Group type: EXPERIMENTAL
Intervention: 12vPHiD‐CV
Number of subjects: 61

Group type: COMPARATOR
Intervention: PHiD‐CV
Number of subjects: 61
Study: 34076869

Group type: EXPERIMENTAL
Intervention: Testicular sperm (Testi)
Number of subjects: 302

Group type: COMPARATOR
Intervention: DGC
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: PICSI
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: MACS
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: DGC and MACS
Number of subjects: 302
Study: 33504410

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 24
Study: 36451469

Group type: EXPERIMENTAL
Intervention: Nao‐Xin‐Tong capsule (NXT)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Bu‐Yang‐Huan‐Wu (BYHW) granule
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Yang‐Yin‐Tong‐Nao granule (YYTN)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study: 34500127

Group type: EXPERIMENTAL
Intervention: Stoss-dosed vitamin D
Number of subjects: 33